Alten Calsoft Labs launches its first initiative for blockchain through its scalable clinical trial platform BioPharma Ledger to address life sciences processes using BlockApps middleware.
Skyhawk enters an agreement with Merck to discover and develop small molecules to modulate RNA splicing, and expands its existing development agreement with Biogen.
The company initiates operations at its new EU headquarters in Dundalk, Ireland after receiving its manufacturing and importation authorization license from the HPRA.
Newly-minted Signant Health named a new CTO, Parexel bolstered its Japan presence, and BioAgilytix’s CEO was appointed to the board of FSD Pharma – a company developing products based on cannabinoids – among other people on the move in June.
Xellia will move US production from its North Carolina manufacturing facility to its site in Ohio to bolster workforce and manufacture generic IV antibiotics.
Cobra and Symbiosis announce the completion of their collaboration on viral vector development and manufacturing, supported by £1.9m Innovate UK grant.
The value generated by the manufacture of medicines has doubled since 2000, with one of the smallest countries in Europe responsible for a significant proportion of the total figure.
CRF Bracket – newly-rebranded as Signant Health – is looking to build momentum around eConsent, rethink the patient’s connection to the supply chain, and build out a stronger analytics platform, says CEO.
The drug discovery, development, and analytical service provider has opened a new facility in Sandwich, UK to support the development and manufacturing of APIs – a market expected to top $270bn by 2026.
The Russian all-cargo airline AirBridgeCargo Airlines (ABC) has expanded its SkyCell partnership through which it will lease SkyCell’s containers as sales of temperature-sensitive products boom.
To investigate blockchain processes and make distribution information retrieval more efficient, the FDA tapped big name companies for a supply chain security pilot program.
Lonza expands its HPAPI production capacity at its Switzerland facility after entering an agreement with AstraZeneca, and invests in manufacturing to establish efficiency.
San Diego, CA-based NanoComposix received its drug manufacturing license which it said will ensure clients are able to use one vendor throughout the product life cycle.
Marken has opened a new depot and increased its logistics warehouse capacity fourfold to accommodate client needs for clinical drug product, clinical drug substance, and medical device storage.
Dassault Systèmes is set to acquire Medidata in an all-cash transaction valued at $5.8bn – a deal which will combine the power of modeling and simulation with data science to “catalyze the next generation of patient-inclusive therapeutics,” says CEO.
Aptar Group acquires two pharmaceutical services companies, Nanopharm and Gateway Analytical, to boost its analytical, testing, and development capabilities.
ElevateBio’s BaseCamp facility will provide “bench-to-bedside” services to its portfolio and partner companies – as the demand for cell and gene therapy CMOs “far outweighs the capacity,” says CEO.
The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.
Vetter’s German sites will be supplied with only CO2 neutral energy from renewable energy sources as the company continues to work towards greater sustainability.
Although the industry may not be among the ‘frontrunners’, Novo Nordisk is seeing the benefits when it comes to recruitment and developing mutually beneficial partnerships, says director.
SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.
Artificial intelligence tools will allow the pharmaceutical companies to make predictions about diseases more effectively than before, says ImaginAB’s CEO.
Marken executive says there is no such thing as a perfect clinical trial supply chain but with strategic planning and innovations there are opportunities to better serve the research industry.
Civica signs a supply agreement with Xellia to manufacture antibiotics in the US, marking the organisation’s first step towards improving the availability of generics in short supply.
Wasdell Group has acquired specialist manufacturer and packager, Honeywood Limited in an aim to build its manufacturing and packaging capacity in the UK to support European supply chain.
As WuXi STA expands its facility footprint in China, a VP of the company explains how global regulatory approvals fit with strategic plans for services to be concentrated geographically.
eClinical technology company, Axiom Real-Time Metrics, will be recapitalized by Great Point Partners to provide eClinical solutions to increase service offerings for Phase I-III clinical trials.
Mispro is expanding its vivarium service network with the opening of its fifth facility, an 18,000 square foot facility in Broad Hollow Bioscience Park, NY.
